ABSTRACT The relationship between the antithrombotic and antiplatelet effects of aspirin is complex, since aspirin influences other systems that protect against thrombosis as well as inhibiting platelet function. We investigated possible cumulative effects of low-dose aspirin on vascular production of prostacyclin in patients with documented atherosclerotic cardiovascular disease. Candidates for coronary artery vein graft bypass ingested 20 mg of aspirin daily during the week before surgery, and platelet aggregation, platelet formation of thromboxane A2 (TXA2), aortic and saphenous vein production of prostacyclin (PGI2), and hemostatic status were measured at the time of the bypass surgery. Low-dose aspirin markedly inhibited platelet aggregation responses and reduced TXA2 generation by greater than 90%, effects similar to those observed with much higher doses of aspirin. Both aortic and saphenous vein production of PGI2 were inhibited by 50% compared with PGI, produced by vascular tissues of control subjects who received no aspirin preoperatively (51 ± 10 pg 6-keto-PGF1J/mg aortic wet weight [mean + SEM] in aspirin-treated subjects vs 130 ± 16 pg/mg in control subjects, and 71 + 8 pg/mg saphenous vein wet weight vs 131 + 17 pg/mg). Blood loss at surgery was not significantly increased by preoperative low-dose aspirin as measured by chest tube drainage (754 ± 229 ml in aspirin-treated subjects vs 645 + 271 ml in control subjects), hematocrit nadir (31. 
MANY STUDIES of the antithrombotic efficacy of aspirin have been conducted, yet controversy over an optimum dosage remains active. Moreover, the relationship between the antiplatelet effects of aspirin and its antithrombotic efficacy has not been clarified. Aspirin inhibits platelet aggregation, decreases the release of vasoactive substances from platelets, and prolongs the bleeding time. These effects result from irrevers-ible inactivation by aspirin of the enzyme, fatty acid cyclooxygenase, in platelets, blocking enzymatic conversion of arachidonic acid into prostaglandin endoperoxides and thence into prostaglandins and thromboxanes.I Since platelets lack protein synthetic capacity, they do not produce new cyclooxygenase after aspirin exposure and remain functionally inhibited throughout their lifespan in the circulation.2 Cyclooxygenase in vascular tissue is also inhibited by aspirin, although the blood vessel cells recover the capacity for prostaglandin production within hours via new cyclooxygenase synthesis.3 '4 In addition to inhibiting vascular production of prostacyclin (PGI2), aspirin also prevents release of vascular plasminogen activator.5 Because aspirin can prevent vascular release of these antithrombotic factors at conventional doses known to inhibit platelet formation of prothrombotic thromboxane A2 (TXA2), it is important to ascertain whether a lower, specifically antiplatelet dose of the drug exists.
Treatment with aspirin (160 mg to 1.8 g daily) alone or in combination with dipyridamole in controlled clinical trials has been observed to decrease arteriovenous shunt thrombosis,6 prevent stroke or transient ischemic attacks,7-10 lower the incidence of myocardial infarction after unstable angina,' decrease graft occlusions after coronary artery bypass surgery,'2, 13 diminish platelet accumulation in prosthetic vascular grafts,'4 prevent pulmonary embolism after hip surgery,'5 and decrease emboli after heart valve replacement. 16 Although 325 mg of aspirin daily decreased the incidence of myocardial infarctions in patients with unstable angina," none of many large clinical trials testing aspirin (1 to 2 g daily) for prevention of recurrent myocardial infarction in survivors of a prior infarct showed clear benefit from the drug. [17] [18] [19] [20] It remains an open question whether nonplatelet effects of higher aspirin dosage might detract from antiplatelet benefits.
Very small doses of aspirin suffice to inhibit platelet aggregation as well as platelet synthesis of TXA2 the potent vasoconstrictor and platelet aggregant substance. In normal subjects 100 mg of oral aspirin taken once inhibited platelet production of TXA2 by more than 95%.2' We reported that a single dose of 80 mg aspirin administered to patients with coronary artery disease produced 95% inhibition of platelet TXA2 generation, inhibited arachidonate-induced platelet aggregation, and abolished the second wave of ADP-or epinephrine-induced aggregation.22 Moreover, normal subjects23 or patients with recent cerebral ischemia24 given only 40 mg/day aspirin had full inhibition of platelet aggregation and 90% suppression of TXA2 within a few days of starting treatment, indicating that low-dose aspirin has a cumulative inhibitory effect on platelets. This study was undertaken to ascertain whether very small repeated oral doses of aspirin administered to patients with atherosclerosis would exert a cumulative inhibitory effect on vascular cyclooxygenase as well as platelet cyclooxygenase. We previously showed that vascular cyclooxygenase production in patients with atherosclerosis was almost completely inhibited by a single "ordinary" dose of aspirin (325 mg) but was not affected by a single dose of 40 mg.22 Therefore 20 mg of aspirin was administered daily to patients with documented atherosclerotic coronary artery disease before scheduled coronary artery bypass graft surgery, a procedure in which early postoperative aspirin ther- apy appears to be beneficial.'2, 1 The effects of lowdose aspirin on platelet aggregation and thromboxane production, on the production of PGI2 by blood vessels, and on hemostatic function were monitored and compared. We found that this low-dose aspirin regimen inhibited platelet function similarly to larger doses and that a cumulative inhibition could also be demonstrated on vascular PGI2 production.
Methods
The study population comprised 20 Kalama- zoo, MI), was measured. The occurrence of spontaneous plate-let aggregation in stirred platelet-rich plasma was also monitored.
Serum thromboxane. Blood drawn into a plain glass tube was allowed to clot at 370 C for 1 hr, after which the serum was separated by centrifugation at 40 C and frozen at -40°C until measurement of released thromboxane B2 (TXB2) by radioimmunoassay as previously described.25 Serum thromboxane elicited in this manner represents the maximal thromboxane production by platelets stimulated by thrombin released by clotting, and is a good measure of platelet capacity to form TXA. 21 Studies of PGI2 synthesis by vascular fragments. Vascular fragments were weighed, washed, and incubated at 370 C in HEPES-buffered saline containing divalent cations in the presence or absence of 25 guM sodium arachidonate for 15 min to obtain stimulated or basal production of PGI.22 PGI2 in the supernatant fluid was measured by radioimmunoassay of 6-keto-PGFi, as previously described.25 When available, additional saphenous vein specimens were also placed in a template chamber, endothelial side uppermost, and incubated with HEPES buffer or buffer containing arachidonate at 370 C to elicit endothelial production of PGI2. The chamber excludes cut tissue edges from study and has previously been shown to measure release of PGI2 released from endothelium rather than from smooth muscle layers of the vessel wall. 26 The chambers were designed and made available by Dr. Eric Grabowski.
Histologic study. Vascular fragments used for the assays were fixed in buffered 10% formalin and embedded in paraffin, and 6 ,gm sections were stained with hematoxylin and eosin. The degree of intimal thickening in aortic sections was used as an index of atherosclerosis and was expressed as the ratio of intimal to medial area. The latter was determined by planimetry by means of a Zeiss MOP-3 image digitizer equipped with a camera lucida attachment. A normal intimal:medial ratio was considered to be 5%o or less.
Statistics. Statistical analysis of data was performed with Student's unpaired t test for comparison between patient groups and with the Kruksal-Wallis test for multiple comparisons. Values for test results are presented as means ± SEM unless otherwise noted. Statistical significance was considered to be demonstrated at p < .05.
Results
Comparison of subject groups. The group of subjects who took the prescribed course of low-dose aspirin and the group of untreated controls were comparable on the bIsis of age, severity of atherosclerosis, other associated diseases, medications, and preoperative laboratory values (tables 1 and 2). The groups also did not differ significantly in duration of cardiopulmonary bypass or number of grafts placed.
Studies with platelets. Platelet aggregation in response to arachidonic acid stimulation was completely inhibited in all subjects who ingested 20 mg of aspirin daily for 1 week, except for a single subject who was found to have been taking ibuprofen, a drug that can interfere with the protracted effects of aspirin on platelets. Similarly, aggregation responses to collagen, ADP, and epinephrine were decreased in all other aspirin-treated subjects. Collagen-induced aggregation averaged 39% of the maximum aggregation response achieved with the endoperoxide analog U44069, which bypasses the aspirin block. The second wave of aggregation in response to ADP and epinephrine was inhibited with preservation of the primary wave. The aggregation pattern observed in these subjects was indistinguishable from that of patients given much higher doses of aspirin, and reflected the typical effects of aspirin on platelets. The extent of inhibition of responses to aggregating agents was similar whether the blood for aggregation studies was drawn 3, 12, or 24 hr after the last dose of aspirin. Slight spontaneous platelet aggregation was observed in three subjects who had taken the low-dose aspirin and in eight control subjects. All subjects in the control group showed full aggregation responses to sodium arachidonate, collagen, ADP, and epinephrine, confirming their lack of aspirin ingestion. Serum TXB2. Serum levels of thromboxane TXB2, representing the maximal generation of TXA2 by platelets during blood clotting at 370 C, were significantly lower (p < .00 1) for all subjects who ingested 20 mg of aspirin daily than serum TXB2 levels of control subjects and averaged 7% of the TXB2 level of control subjects. The observed serum TXB2 level varied with the interval between the last ingestion of aspirin and blood sampling. Lowest levels were obtained in blood sampled 3 to 5 hr after the last dose, with higher levels in samples taken 12 and 24 hr after the last dose ( figure  1 ). At 24 hr the serum TXB2 levels in aspirin-treated subjects averaged 10% of those in control subjects, whereas at 3 hr they averaged 3% of control values.
PGI2 production by vascular tissue. Aortic fragments removed from aspirin-treated subjects and incubated with sodium arachidonate produced 78 + 25 pg 6-keto-PGF1a/mg of aortic tissue when the last aspirin figure 2 ). The aortic 6-keto-PGFl level was significantly lower than the control level at both intervals after low-dose aspirin ingestion (p < .001 for all subjects, p < .02 for those receiving aspirin 3 hr before surgery). The weight of aortic fragments was similar in the treated and control groups, 19.0 ± 7.8 mg for aspirin-treated subjects and 16.5 ± 9.5 mg for control subjects.
Segments of saphenous vein removed from aspirintreated subjects and incubated with sodium arachidonate produced 71 ± 8 pg 6-keto-PGFJa/mg tissue when the last dose of aspirin was taken 24 hr earlier and 39 ± 7 pg/mg when the last dose of aspirin was taken 3 to 5 hr before tissue sampling. Saphenous vein fragments from control subjects produced 139 ± 17 pg/mg tissue .....apirn 2mg. x7 FIGURE 1. Effect of low-dose aspirin (ASA) ingestion on serum TXB2. Data are means + SEM. Decrease in serum TXB2 is dependent on the interval between the last dose of aspirin and measurement in clotted blood. The TXB2 levels for all aspirin-treated subjects are significantly lower than those for control subjects (p < .001, KruskalWallis) and also differ from one another (p < .01). The capacity of endothelium to release 6-keto-PGFia as a function of the interval after the last dose of aspirin was compared for four subjects whose tissues were obtained 3 hr after the last aspirin dose and for four subjects whose tissues were obtained 24 hr after the last aspirin dose, with the use of segments of saphenous vein tested in a template chamber designed to exclude the contribution of PGI2 produced by smooth muscle layers of the vessel. As seen in table 3, endothelial production of 6-keto-PGF1, was inhibited by 58% in veins removed 3 hr after aspirin but was similar to control production in veins removed 24 hr after aspirin.
Hemostatic data. The template bleeding time before surgery was 6.1 ± 1.7 min for aspirin-treated subjects and 4.4 ± 1.0 min for control subjects. These values both lie within the accepted normal range (2 to 7 min); however, the value for the aspirin-treated group is significantly longer (p < .001).
Perioperative blood loss was similar in aspirin-treated and in control subjects (table 2). Chest tube drainage at 8 hr after completion of surgery was almost identical in the two groups (300 ± 229 ml [mean ± SD] in aspirin-treated subjects and 315 ± 119 ml in control subjects); total chest tube drainage was slightly greater (754 ± 424 ml) in aspirin-treated subjects, with a wider scatter than in control subjects (645 ± 260 ml), but the difference was not statistically significant (p > .4). Total duration of chest tube drainage did not differ between the groups. Transfusion requirements were similar in the two groups (2.2 ± 1.3 units of packed red cells in aspirin-treated subjects and 2.2 e0-l mU ± 1.7 units in control subjects [mean ± SD]). The postoperative nadirs of hematocrit and platelet count were similar for aspirin-treated and control groups, with hematocrit falling an average of 13% in aspirintreated group and 10% in control subjects, and the platelet count decreasing by 96,000 and 99,000, respectively (table 2) . Pathologic evaluation of atherosclerosis. Histologic examination of the aortic fragments showed that the degree of atherosclerosis was mild, with an average intimal:medial area ratio of 13.0 + 6.9% for aspirintreated subjects and 15.3 ± 10.7% for control subjects (p = NS). This represented mainly intimal thickening, with minimal cellular infiltration. Cholesterol deposits were rare and cholesterol clefts were not encountered. No correlation was observed between the degree of intimal thickening and the amount of 6-keto-PGF, formed by the tissue. No correlation was observed between the amount of intimal thickening and the serum cholesterol level for either group of subjects.
Discussion
Preoperative treatment of coronary artery bypass patients with low-dose aspirin for 1 week resulted in significant inhibition of platelet function and of vascular PGI2 production. Platelet aggregation was inhibited in the pattern typical for aspirin, and platelet formation of TXA2 was only 10% that of untreated control subjects. Both aortic and saphenous vein tissue removed from subjects treated with 20 mg/day aspirin for 1 week produced less than 50% as much PGI2 when stimulated with arachidonate than did tissues removed from subjects who did not receive any preoperative aspirin. These results indicate that a cumulative effect of very low doses of aspirin on both platelet and vascular cyclooxygenase occurs, since in the same clinical preparation a single dose of 80 mg inhibited only venous but not arterial PGI2 production (figure 4) and a single dose of 40 mg failed to inhibit either aortic or venous PG12 formation. 22 The inhibition of platelet aggregation and of thromboxane release from platelets in subjects who took 20 mg/day aspirin for a week implies that the platelets of patients with atherosclerotic coronary artery disease are not more resistant than platelets of normal subjects to the inhibitory effects of once-daily, low-dose, oral aspirin. Previous studies in normal young subjects given 20 to 40 mg of aspirin daily indicated that cumulative inhibition of TXA2 synthesis by 95% from preaspirin levels was regularly achieved after three to four such daily doses. 4 The implication of these findings is that normal endothelium has the capacity to "recover" rapidly from daily exposure to low-dose aspirin in terms of producing PGI2 at the luminal-blood interface. Whether areas of vessel involved in atherosclerotic plaque formation or lacking normal endothelium might show a different, slower, pattern of recovery of PGI2 formation remains to be determined.
In conclusion, it appears clear that a low-dose regimen of daily oral aspirin will profoundly inhibit platelet aggregation and thromboxane synthesis in patients with coronary artery disease and at the same time will partially depress vascular PGI2 production. Administration of low-dose aspiriin preoperatively does not appear to compromise hemostasis. Endothelium appears to overcome the aspirin-induced cyclooxygenase block more rapidly than vascular smooth muscle, suggesting another possible antithrombotic feature of the vascular lining. These data strongly suggest that the dosage and schedule of aspirin administration designed as antiplatelet therapy must also be examined for cumulative inhibitory effects on vascular and other tissues.
